Dr Timo Van Den Berg | Professor of Immunotherapy, Head of Department of Blood Cell Research
Sanquin Research and Landsteiner Laboratory

Dr Timo Van Den Berg, Professor of Immunotherapy, Head of Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory

My group is interested in antibody immunotherapy against cancer. Our major aim is to improve treatment of cancer patients with therapeutic antibodies in order to reduce the need for non-specific agents, such as chemotherapeutics. We have identified CD47-SIRPa interactions as an innate immune checkpoint during antibody therapy in cancer. Work is ongoing to explore the mechanisms of antibody-dependent cancer cell destruction by innate immune cells and the ways in which this can be further improved.

Appearances:



WIC 2017 Day 1, Tuesday 31st October 2017 @ 17:30

The CD47-SIRPα axis as an innate immune checkpoint in cancer

  • Immune cell-mediated destruction of antibody-opsonized cancer cells is resticted by CD47-SIRP interactions.
  • Mechanistic insights
  • Applicability for improving antibody therapy in cancer
 

back to speakers